Who are Biologic TNFi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abrilada, Humira, CYCLOSPORINE VS INFLIXIMAB, Tapered doses of TNFi, infliximab, etanercept, adalimumab, Etanercept (ETN).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/biologic-tnfi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Biologic TNFi — Competitive Intelligence Brief

Biologic TNFi (Biologic TNFi) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF inhibitor. Area: Immunology.

phase 3 TNF inhibitor TNF-alpha Immunology Biologic Live · refreshed every 30 min

Target snapshot

Biologic TNFi (Biologic TNFi) — Pfizer. A TNF inhibitor biologic that blocks tumor necrosis factor (TNF) to reduce inflammatory immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Biologic TNFi TARGET	Biologic TNFi	Pfizer	phase 3	TNF inhibitor	TNF-alpha
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
CYCLOSPORINE VS INFLIXIMAB	CYCLOSPORINE VS INFLIXIMAB	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab)	Calcineurin (cyclosporine); TNF-alpha (infliximab)
Tapered doses of TNFi	Tapered doses of TNFi	University Health Network, Toronto	marketed	TNF inhibitor (tapered dosing strategy)	TNF-alpha
infliximab, etanercept, adalimumab	infliximab, etanercept, adalimumab	University Hospital, Strasbourg, France	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Etanercept (ETN)	Etanercept (ETN)	University of Leeds	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF inhibitor class)

University Hospital, Montpellier · 2 drugs in this class
Amgen · 1 drug in this class
Biogen · 1 drug in this class
Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
National Eye Institute (NEI) · 1 drug in this class
Abbott · 1 drug in this class
Spanish Clinical Pharmacology Society · 1 drug in this class
Takeda · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Biologic TNFi — Competitive Intelligence Brief. https://druglandscape.com/ci/biologic-tnfi. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab